Devita, Hellman, and Rosenberg's Cancer

LWBK1006-11 LWW-Govindan-Review November 24, 2011 11:21

128 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 11.22. EC is a 61-year-old male with relapsed follicular lymphoma who is about

to proceed with ibritumomab therapy. Which of the following statements

regarding ibritumomab therapy is INCORRECT?

A. Severe cutaneous and mucocutaneous skin reactions have been

reported up to 4 months following ibritumomab therapy.

B. Ibritumomab can be safely administered to patients with impaired

bone marrow reserve.

C. On day 1 of therapy only, patients receive ibritumomab complexed

with indium-111 to assess biodistribution of the monoclonal anti-

body.

D. Ibritumomab is a monoclonal antibody directed against the CD20

antigen used to deliver a radioactive isotope to targeted cells.

Question 11.23. A 45-year-old male is beginning treatment with high-dose interleukin

(IL)-2 for renal cell carcinoma. He is ordered to receive 0.6 million

units/kg/dose intravenously every 8 hours×14 doses. Which of the fol-

lowing is TRUE?

A. Subsequent IL-2 doses should be reduced by 25% in the setting of

toxicity.

B. For patients developing moderate-to-severe lethargy or somnolence,

it is appropriate to continue treatment up to a total of 14 doses.

C. IL-2 therapy is associated with capillary leak syndrome that may

begin immediately after initiation of treatment and result in death.

D. In the setting of IL-2-induced repetitive seizures, treatment can be

resumed upon initiation of antiseizure medication and seizure cessa-

tion.

Question 11.24. Which of the following statements regarding antiangiogenesis agents is

CORRECT?

A. Lenalidomide was the first angiogenesis inhibitor approved by the

FDA for cancer treatment.

B. Vorinostat, celecoxib, and bortezomib may all be referred to as exclu-

sive angiogenesis inhibitors.

C. Proangiogenic factors include endostatin, angiostatin, and thrombo-

spondin.

D. Resistance to vascular endothelial growth factor inhibitors has been

seen secondary to increased expression of proangiogenic factors.

Question 11.25. Which of the following adjuvant endocrine therapies would be the most

appropriate for use in a postmenopausal woman with stage II ER/PR (+)

breast cancer?

A. Tamoxifen for 5 years

B. Anastrozole for 5 years

C. Goserelin for 5 years

D. Bicalutamide for 5 years